IP Verse

Vegf Antagonist Formulations Suitable For Intravitreal Administration

Patent No. EP2944306 (titled "Vegf Antagonist Formulations Suitable For Intravitreal Administration") was filed by Regeneron Pharmaceuticals on Jun 14, 2007. The application was issued on Jan 27, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTOct 27, 2021BOULT WADE TENNANT
DR H ULRICH DORRIESOct 27, 2021SCHIMMEL
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBOct 26, 2021WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2944306

REGENERON PHARMACEUTICALS
Application Number
EP15169936A
Filing Date
Jun 14, 2007
Status
Granted And Under Opposition
Dec 25, 2020
Publication Date
Jan 27, 2021
External Links
Slate, Register , Google Patents